Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-598: pembrolizumab + ipilimumab vs pembrolizumab + placebo in previously untreated PD-L1-high metastatic NSCLC
2016-004364-20Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + ipilimumab with Pembrolizumab + placebo (2 arms). Primary endpoint: Overall survival. Started Sep 2017; status: completed.
02
Drugs
pembrolizumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-004364-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004364-20.